Skip to main content

Will State Action on Biosimilars Thwart Anticipated Savings for Health Care Programs

Bloomberg BNA

Aug
5
2015

Date: August 5, 2015

Time: 1:00PM

Topics

  • Will State Action on Biosimilars Thwart Anticipated Savings for Health Care Programs

Mintz Levin attorneys Ellyn Sternfield, Theresa Carnegie, and Joanne Hawana will be presenting a Bloomberg BNA Webinar entitled, "Will State Action on Biosimilars Thwart Anticipated Savings for Health Care Programs?" on August 5th. They discuss the state action on biosimilars, potential cost savings for Health Care Programs, the role of the FDA, and the CMS guidance addressing Medicare and Medicaid coverage and reimbursement of FDA-approved biosimilar drug products.

Educational Objectives:

  • Discuss the state action on biosimilars
  • Explore potential cost savings for health care programs
  • Address the role of the Federal Drug Administration’s approval of biosimilar drug products
  • Review the Centers for Medicare and Medicaid services guidance addressing Medicare and Medicaid coverage and reimbursement of FDA-approved biosimilar drug products

Speakers

Theresa C. Carnegie is a Mintz attorney who advises health care clients on a wide array of transactional, regulatory, compliance, fraud and abuse matters, and health law issues. She counsels health plans, pharmacy benefit managers, pharmacies, device manufacturers, and distributors.
Ellyn L. Sternfield is a Mintz Special Counsel with an extensive background in government health care enforcement. She provides insight to clients with compliance concerns and helps clients facing potential state or federal investigations.
Professional Cropped Hawana Joanne Mintz

Joanne S. Hawana

Panelist

Joanne S. Hawana counsels global Mintz clients on regulatory and distribution-related considerations for new FDA-regulated products. She also advises clients on the business impacts of new federal and state actions on food, drugs, cosmetics, electronic nicotine systems, and medical devices.